Rajeev Dadoo, PhD, invests primarily in biotechnology and healthcare-technology companies across stages from Series A to late-stage. See contact routes.
Rajeev Dadoo, PhD, invests primarily in biotechnology and healthcare-technology companies across stages from Series A to late-stage growth, focusing on therapeutics with strong fundamentals and novel disease-treatment approaches. His notable portfolio includes Renalys Pharma (Series A, $38M), ARS Pharmaceuticals (Series D, $55M), Nimbus Therapeutics (Private Equity, $640M total), and Dren Bio (Series A/B, $130M total). Dadoo’s distinctive thesis emphasizes an “operator-first,” back-and-build approach that leverages his operational experience from GSK and Genentech to support entrepreneurs translating innovative science into medicines.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Redwood City.
Investors like Rajeev Dadoo · Full investor directory · Investor access · Company funding database